PubMed
Hexarelin, a synthetic growth hormone-releasing peptide, vs GHRH in GH-deficient adults
Ghigo E, Arvat E, Muccioli G, et al. Eur J Endocrinol. 1996
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 48% · Mixed 44% · Unfavorable overall 8%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 25–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 58% said they felt similar to their last entry, 28% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 32 days · Based on 269 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 67% · Mixed 18% · Unfavorable overall 15%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.05 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 29% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 15 days · Based on 168 repeat reporters
Published sources linked on the Hexarelin and ITPP wiki pages.
PubMed
Ghigo E, Arvat E, Muccioli G, et al. Eur J Endocrinol. 1996
PubMed
Bisi G, Podio V, Valetto MR, et al. Growth Horm IGF Res. 2001
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Kolovou GD, Kolovou V, Mavrogeni S. BioMed research international. 2014
PubMed
Mao Y, Tokudome T, Kishimoto I. Journal of geriatric cardiology : JGC. 2014
PubMed
Schneider MA, Linecker M, Fritsch R, et al. Nat Commun. 2021
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2015